Injectable monoclonal antibody formulation targeting PCSK9 protein, administered subcutaneously in cardiology clinics and hospitals. Employed by healthcare providers for lipid disorder management in cardiovascular care facilities. Supplied by pharmaceutical manufacturers to wholesalers, distributors, and institutional pharmacies.